NYSE$STE
STERIS PLC · Q1 2025 earnings
Q1 2025 earnings · · Investor relations
Briefing
Announced financial results for fiscal 2025 first quarter, demonstrating revenue growth and strong segment performance.
STERIS reported an 8% increase in total revenue to $1.3 billion and a 6% growth in constant currency organic revenue. As reported EPS increased to $1.41, while adjusted EPS reached $2.03. The company reiterated its fiscal 2025 outlook, expressing confidence in achieving full-year guidance.
- Total revenue from continuing operations increased by 8%, with constant currency organic revenue growing by 6%.
- As reported EPS from continuing operations increased to $1.41, and adjusted EPS increased to $2.03.
- Healthcare revenue grew by 10%, driven by improvements in consumable and service revenue.
- Fiscal 2025 outlook has been reiterated, indicating continued confidence in delivering full-year guidance.
Headline financials
Revenue & EPS history
STERIS · Revenue · Quarterly
$1.28B
Revenue by segment
STERIS · $1.59B total across 3 segments · Q4 2027
- Healthcare$1.14B—71.5%
- Applied Sterilization Technologies$289M—18.2%
- Life Sciences$163M—10.3%
Forward guidance
STERIS continues to expect as reported revenue from continuing operations to increase 6.5-7.5%. Constant currency organic revenue from continuing operations is anticipated to increase 6-7%. Adjusted earnings per diluted share from continuing operations is anticipated to be in the range of $9.05 to $9.25. Capital expenditures are anticipated to be approximately $360 million and free cash flow is expected to be approximately $700 million.
Tailwinds
- As reported revenue from continuing operations is expected to increase 6.5-7.5%.
- Currency is expected to be neutral to revenue in fiscal 2025.
- Constant currency organic revenue from continuing operations is anticipated to increase 6-7%.
- Adjusted earnings per diluted share from continuing operations is anticipated to be in the range of $9.05 to $9.25 compared with $8.20 in adjusted earnings from continuing operations in fiscal 2024.
- Free cash flow is expected to be approximately $700 million.
Headwinds
- Total annual revenue for the divested business in fiscal 2024 was approximately $35 million which will be excluded from constant currency organic revenue growth from continuing operations in fiscal 2025.
- Capital expenditures are anticipated to be approximately $360 million.
- The fiscal 2025 outlook assumes an effective tax rate of approximately 23%.
- Uncertainties related to tax treatments under the TCJA and the IRA.
- The possibility that Pillar Two Model Rules could increase tax uncertainty and adversely impact STERIS's provision for income taxes and effective tax rate and subject STERIS to additional income tax in jurisdictions who adopt Pillar Two Model Rules.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
+0.5%
Avg return
Earnings day
+1.0%
Avg return
5 days after
+1.3%
Avg return
30 days after
59%
38 / 64 earnings
Positive
+12.9%
Q4 2014
Best reaction
-11.4%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2027 | +0.0% | +7.2% | +2.8% | |
| Q3 2026 | -7.7% | -7.4% | -12.8% | |
| Q2 2026 | +7.0% | +9.7% | +8.3% | |
| Q4 2025 | +8.6% | +10.1% | +6.1% | |
| Q3 2025 | +2.1% | +1.1% | +5.4% | |
| Q2 2025 | -5.2% | -2.5% | -5.1% | |
| Q1 2025 | -1.8% | -0.8% | +0.5% | |
| Q4 2024 | +6.2% | +9.2% | +6.6% | |
| Q3 2024 | -2.5% | -0.4% | +3.4% | |
| Q2 2024 | -5.1% | -8.4% | -7.1% | |
| Q1 2024 | +1.0% | +0.2% | +1.8% | |
| Q4 2023 | +11.2% | +12.7% | +10.6% | |
| Q3 2023 | -11.4% | -9.5% | -18.2% | |
| Q2 2023 | +3.5% | +2.6% | +17.3% | |
| Q1 2023 | -8.8% | -4.7% | -10.0% | |
| Q4 2022 | +1.4% | +1.2% | +2.6% | |
| Q3 2022 | +4.6% | +1.3% | -2.1% | |
| Q2 2022 | -5.5% | -4.8% | -6.4% | |
| Q1 2022 | +0.6% | +1.2% | +0.2% | |
| Q4 2021 | -3.6% | -3.1% | +1.9% | |
| Q3 2021 | -1.9% | -1.7% | -8.1% | |
| Q2 2021 | -0.5% | +2.5% | +8.8% | |
| Q1 2021 | -1.0% | -3.4% | +2.5% | |
| Q4 2020 | +1.2% | +7.0% | +1.8% | |
| Q3 2020 | +6.1% | +10.2% | -5.0% | |
| Q2 2020 | +2.3% | +2.6% | +8.4% | |
| Q1 2020 | +3.0% | +4.1% | +3.0% | |
| Q4 2019 | +1.1% | +3.2% | +10.2% | |
| Q3 2019 | +1.9% | +3.1% | +3.6% | |
| Q2 2019 | +7.0% | +7.4% | +5.4% | |
| Q1 2019 | -0.7% | -1.1% | -1.9% | |
| Q4 2018 | +4.7% | +4.6% | +8.6% | |
| Q3 2018 | -4.7% | -2.8% | +7.8% | |
| Q2 2018 | -6.0% | -6.6% | -3.9% | |
| Q1 2018 | +4.9% | +3.3% | +5.8% | |
| Q4 2017 | +1.4% | -0.4% | +6.4% | |
| Q3 2017 | -6.5% | -5.7% | -3.4% | |
| Q2 2017 | -3.0% | +0.5% | -2.0% | |
| Q1 2017 | -1.6% | -1.9% | -2.0% | |
| Q4 2016 | -0.5% | — | — | |
| Q3 2016 | -1.9% | — | — | |
| Q2 2016 | +6.4% | — | — | |
| Q1 2016 | +0.7% | — | — | |
| Q4 2015 | +2.5% | — | — | |
| Q3 2015 | +1.1% | — | — | |
| Q2 2015 | +3.5% | — | — | |
| Q1 2015 | +0.3% | — | — | |
| Q4 2014 | +12.9% | — | — | |
| Q3 2014 | +0.5% | — | — | |
| Q2 2014 | -3.6% | — | — | |
| Q1 2014 | -3.6% | — | — | |
| Q4 2013 | +8.3% | — | — | |
| Q3 2013 | +1.4% | — | — | |
| Q1 2013 | +1.4% | — | — | |
| Q2 2013 | +1.1% | — | — | |
| Q4 2012 | -0.3% | — | — | |
| Q3 2012 | +0.8% | — | — | |
| Q1 2012 | +0.8% | — | — | |
| Q2 2012 | -4.4% | — | — | |
| Q4 2011 | +0.3% | — | — | |
| Q3 2010 | +0.2% | — | — | |
| Q1 2010 | +0.2% | — | — | |
| Q2 2010 | +0.8% | — | — | |
| Q4 2010 | -0.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro